findmyKOL
Clinical trialNCT00426998CompletedPhase 2Interventional

Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD

SponsorRetinal Consultants Medical GroupEnrollment30Choroidal NeovascularizationMacular Degeneration
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this research study is to compare different timing therapies of Verteporfin with Bevacizumab to treat choroidal neovascularization (CNV) due to age-related macular degeneration (AMD).

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Joel A Pearlman, M.D., Ph. D.

    Retinal Consultants Medical Group, Inc.

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Retinal Consultants Medical Group, Inc.

    Sacramento, California, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Apr 2006
Primary completion
—
Completion
—
Last update posted
26 Jan 2007
Registered enrollment
30
Registry id
NCT00426998

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.